Lawrence Corey: Difference between revisions
mNo edit summary |
m Content added to seventh paragraph; citations added |
||
| Line 12: | Line 12: | ||
In July 2008, Dr. Corey co-founded the biotechnology company Immune Design, to develop vaccines built on emerging understanding of the human immune system. The Company's additional founders include Dr. [[David Baltimore]], Nobel Laureate, former president of [[Caltech]], and a leading immunologist; Dr. Steven Reed, founder of the [[Infectious Disease Research Institute]] (IDRI), Dr. Lili Yang of Caltech, and Dr. Pin Wang of [[University of Southern California]].<ref name="Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company">{{cite news|title=Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company|url=http://www.xconomy.com/seattle/2008/06/23/immune-design-led-by-star-scientists-raises-18-million-to-build-vaccine-company/|publisher=xconomy}}</ref> On July 30, 2010, Dr Corey was named the fourth president of the [[Fred Hutchinson Cancer Research Center]].<ref name="Larry Corey, Virus Hunter With Midwest Roots, Seeks to Unleash Health Innovation at Hutch">{{cite news|title=Larry Corey, Virus Hunter With Midwest Roots, Seeks to Unleash Health Innovation at Hutch|url=http://www.xconomy.com/seattle/2010/08/02/larry-corey-virus-hunter-with-midwest-roots-seeks-to-unleash-health-innovation-at-hutch/|publisher=xconomy}}</ref> |
In July 2008, Dr. Corey co-founded the biotechnology company Immune Design, to develop vaccines built on emerging understanding of the human immune system. The Company's additional founders include Dr. [[David Baltimore]], Nobel Laureate, former president of [[Caltech]], and a leading immunologist; Dr. Steven Reed, founder of the [[Infectious Disease Research Institute]] (IDRI), Dr. Lili Yang of Caltech, and Dr. Pin Wang of [[University of Southern California]].<ref name="Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company">{{cite news|title=Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company|url=http://www.xconomy.com/seattle/2008/06/23/immune-design-led-by-star-scientists-raises-18-million-to-build-vaccine-company/|publisher=xconomy}}</ref> On July 30, 2010, Dr Corey was named the fourth president of the [[Fred Hutchinson Cancer Research Center]].<ref name="Larry Corey, Virus Hunter With Midwest Roots, Seeks to Unleash Health Innovation at Hutch">{{cite news|title=Larry Corey, Virus Hunter With Midwest Roots, Seeks to Unleash Health Innovation at Hutch|url=http://www.xconomy.com/seattle/2010/08/02/larry-corey-virus-hunter-with-midwest-roots-seeks-to-unleash-health-innovation-at-hutch/|publisher=xconomy}}</ref> |
||
One of Corey’s major scientific initiatives has been to study and develop better therapy for the treatment and prevention of infectious disease associated cancers such as [[Kaposi sarcoma]] and [[Burkitt lymphoma]]<ref name="Part IV: The Infectious Connection">{{cite news|title=Part IV: The Infectious Connection|url=http://www.pri.org/stories/2012-12-06/part-iv-infectious-connection|publisher=PRI}}</ref>. In 2005, Corey launched a partnership between Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute.<ref name="It’s the people who make us shine">{{cite news|title=It’s the people who make us shine|url=http://www.fredhutch.org/en/news/center-news/2015/05/fred-hutch-uci-uganda-new-cancer-center.html|agency=Fred Hutch News Service}}</ref> In May 2015, that partnership led to the opening of the first comprehensive cancer center jointly constructed by U.S. and African institutions in sub-Saharan Africa.<ref name="It’s the people who make us shine" /> Corey also was a cofounder of [[Juno Therapeutics]], a company devoted to using genetically engineered T cells to fight cancer.<ref name="New cancer research startup Juno Therapeutics raises $134M to push total funding past $300M">{{cite news|title=New cancer research startup Juno Therapeutics raises $134M to push total funding past $300M|url=http://www.geekwire.com/2014/juno-raises-134m-pushes-total-funding-past-300m/|publisher=geekwire.com}}</ref> |
|||
In addition to his professorships at the University of Washington, Corey is currently principal investigator of the US [[HIV Vaccine Trials Network]] and holder of the Lawrence Corey Endowed Chair in Medical Virology at the University of Washington. In 2008, he was elected to the [[Institute of Medicine]] of the (US) [[United States National Academy of Sciences|National Academy of Sciences]]. Dr. Corey is one of the most highly cited and funded investigators in the United States. He has authored 12 books and more than 600 scientific publications and is a member of numerous scientific committees and editorial boards, including the [[National Cancer Institute]] Board of Scientific Counselors for Basic Sciences. |
In addition to his professorships at the University of Washington, Corey is currently principal investigator of the US [[HIV Vaccine Trials Network]] and holder of the Lawrence Corey Endowed Chair in Medical Virology at the University of Washington. In 2008, he was elected to the [[Institute of Medicine]] of the (US) [[United States National Academy of Sciences|National Academy of Sciences]]. Dr. Corey is one of the most highly cited and funded investigators in the United States. He has authored 12 books and more than 600 scientific publications and is a member of numerous scientific committees and editorial boards, including the [[National Cancer Institute]] Board of Scientific Counselors for Basic Sciences. |
||
Revision as of 23:04, 30 November 2015
 |
Lawrence Corey (born February 14, 1947), is a member of the vaccine and infectious disease division and President and Director Emeritus of Fred Hutchinson Cancer Research Center[1] in Seattle Washington. He also serves as founding director and co-principal investigator of the HIV Vaccine Trials Network[2]. In addition, Corey is professor of medicine and laboratory medicine at the University of Washington[3].
The American physician-scientist is an internationally recognized expert in virology, immunology and vaccine development[4]. His discoveries over the past 30 years are cited as having deepened the understanding of both the pathogenesis and treatment of diseases caused by viruses, especially human immunodeficiency virus (HIV) and herpesviruses[4]. Corey has pioneered some of the most significant advances in the creation of safe and effective antivirals for herpes viruses, HIV, and hepatitis infections, the testing of experimental vaccines for HIV and genital herpes, and the designing of new methods for diagnosing and monitoring therapies for viral infections[5].
Education and career
Corey received a B.A. (1967) and M.D. (1971) from the University of Michigan, and received postgraduate training at the University of Michigan, University of Washington, and the U. S. Centers for Disease Control and Prevention.[6] In the early 1980s Corey worked with Nobel Prize-winning biochemist and pharmacologist Dr. Gertrude Elion to demonstrate that an antiviral that was selective and specific for a viral-specified enzyme could be safely and effectively administered to control a chronic viral infection (herpes simplex virus-2). These studies were directly responsible for the subsequent successful quest of the pharmaceutical and medical sciences communities to develop effective antiviral therapy for hepatitis B and HIV.[7]
In 1987 Corey directed the AIDS Clinical Trials Group, or ACTG, which conducted pivotal clinical trials confirming the use of the antiretroviral drug AZT to reduce maternal-fetal transmission of HIV and the usefulness of highly active antiretroviral therapy (HAART).[4] His research group was the first to identify an association between the virus that causes genital herpes (herpes simplex virus) and HIV. Through the ACTG he also was the first to lead the integration of community members into clinical research activities.[4]
In the mid-1990s, Corey increasingly focused his work in the area of vaccine development, and in 1998 worked with the US National Institute of Allergy and Infectious Diseases to develop a global clinical trials group to speed the development of HIV vaccines.[4] In 2002, Corey became the major driver in conceiving of the Global HIV Vaccine Enterprise. The Enterprise is one of the few scientific programs that is overseen by leaders of the major industrialized countries of the world.[4]
In July 2008, Dr. Corey co-founded the biotechnology company Immune Design, to develop vaccines built on emerging understanding of the human immune system. The Company's additional founders include Dr. David Baltimore, Nobel Laureate, former president of Caltech, and a leading immunologist; Dr. Steven Reed, founder of the Infectious Disease Research Institute (IDRI), Dr. Lili Yang of Caltech, and Dr. Pin Wang of University of Southern California.[8] On July 30, 2010, Dr Corey was named the fourth president of the Fred Hutchinson Cancer Research Center.[9]
One of Corey’s major scientific initiatives has been to study and develop better therapy for the treatment and prevention of infectious disease associated cancers such as Kaposi sarcoma and Burkitt lymphoma[10]. In 2005, Corey launched a partnership between Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute.[11] In May 2015, that partnership led to the opening of the first comprehensive cancer center jointly constructed by U.S. and African institutions in sub-Saharan Africa.[11] Corey also was a cofounder of Juno Therapeutics, a company devoted to using genetically engineered T cells to fight cancer.[12]
In addition to his professorships at the University of Washington, Corey is currently principal investigator of the US HIV Vaccine Trials Network and holder of the Lawrence Corey Endowed Chair in Medical Virology at the University of Washington. In 2008, he was elected to the Institute of Medicine of the (US) National Academy of Sciences. Dr. Corey is one of the most highly cited and funded investigators in the United States. He has authored 12 books and more than 600 scientific publications and is a member of numerous scientific committees and editorial boards, including the National Cancer Institute Board of Scientific Counselors for Basic Sciences.
Research
Corey’s early research dealt with various areas of virology, including identification of diagnostic methods for genital herpes and participation in development of effective treatments. Between 1988-1998, Corey published a series of key studies showing the association between infection with herpes simplex virus type 2 (HSV-2) and HIV-1,[13][14]
These studies led to pilot and large sale clinical trials of anti-HSV-2 therapy to reduce HIV acquisition and transmission [15] Corey also published landmark papers showing the effectiveness of acyclovir in the treatment of genital herpes,[16][17]
His current work includes the coordination of clinical trials sites and laboratories for Phase 1-3 trials of HIV vaccines. He continues to do research in defining persistent reservoirs of HIV infection, prevention of CMV and HHV-6 infections in immunocompromised hosts, epidemiological studies of the relationship between HSV and HIV infection, and, in general, development of new technologies for the diagnosis and treatment of viral infections.
Honors
Dr. Corey is a member of the editorial board of the New England Journal of Medicine. He is a fellow of the Infectious Diseases Society of America and a member of the American Epidemiological Society, American Society for Clinical Investigation, and the Association of American Physicians. In addition, he is the recipient of the Pan American Society’s Clinical Virology Award, the American Society for STD Research’s Parran Award, and the University of Michigan Medical School’s Distinguished Alumnus Award. In 2008, Dr. Corey was elected to the Institute of Medicine, a branch of the National Academy of Sciences. In 2012, he was elected to membership in the American Academy of Arts and Sciences.
Selected works
Casper C, Krantz E, Selke S, Kuntz S, Wang J, Huang ML, Pauk JS, Corey L, Wald A (2007) Frequent asymptomatic mucosal replication of human herpesvirus 8 in immunocompetent men, The Journal of Infectious Diseases, 195 (30-36).
Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, Corey L, Coombs RW (2007) Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes, The American Journal of Pathology, 170 (478-489).
Zerr DM, Meier AS, Selke SS, Frenkel LM, Huang ML, Wald A, Rhoads M, Nguy L, Bornemann R, Morrow RA, Corey L (2005) A population-based study of primary human herpesvirus 6 infection, The New England Journal of Medicine, 352, 768-776.
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group (2004) Once daily valacyclovir to reduce the risk of transmission of genital herpes, The New England Journal of Medicine, 350, 11-20.
Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, Haynes BF, Baltimore D, Collins C, Douglas RG, Esparza J, Francis DP, Ganguly NK, Gerberding JL, Johnston MI, Kazatchkine MD, McMichael AJ, Makgoba MW, Pantaleo G, Piot P, Shao Y, Tramont E, Varmus H, Wasserheit JN (2003) The need for a global HIV vaccine enterprise, Science, 300, 2036-2039.
Wald A, Langenberg AGM, Link K, Izu A, Ashley R, Warren T, Tyring S, Douglas JM, Corey L (2001) Effect of condoms on reducing the transmission of herpes simplex virus type-2 from men to women, JAMA, 285, 3100-3106
Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L (2000) Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons, The New England Journal of Medicine, 342(12), 844-50
McElrath M J, Corey L, Greenberg P D, Matthews T J, Montefiori D C, Rowen L, Hood L, Mullins JI (1996). Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen, Proceedings of the National Academy of Sciences (USA), 93(9), 3972-7.
References
- ^ "Larry Corey, MD, Fred Hutchinson Cancer Research Center".
- ^ "HIV Vaccine Trials Network".
- ^ "Lawrence Corey, University of Washington".
- ^ a b c d e f "Larry Corey, virologist".
- ^ "Larry Corey, HIV Vaccine Trials Network".
- ^ "What Will it Take to Achieve an AIDS-free World?". The Lancet.
- ^ "Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company". xconomy.
- ^ "Larry Corey, Virus Hunter With Midwest Roots, Seeks to Unleash Health Innovation at Hutch". xconomy.
- ^ "Part IV: The Infectious Connection". PRI.
- ^ a b "It's the people who make us shine". Fred Hutch News Service.
- ^ "New cancer research startup Juno Therapeutics raises $134M to push total funding past $300M". geekwire.com.
- ^ Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. "The association between genital ulcer disease and acquisition of HIV infection in homosexual men." JAMA. 1988 Sep 9;260(10):1429-33.
- ^ Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998 Jul 1;280(1):61-6.
- ^ Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-799.
- ^ Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. "A trial of topical acyclovir in genital herpes simplex virus infections." N Engl J Med. 1982 Jun 3;306(22):1313-9.
- ^ Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, Fahnlander A, Remington M, Winter C, Corey L. "A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection." N Engl J Med. 1984 Jun 14;310(24):1551-6.